Daraxonrasib doubles survival in metastatic pancreatic cancer in Phase 3 RASolute 302 trial
An oral RAS(ON) inhibitor doubled median survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial. Median overall survival reached 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, a 60 percent reduction in risk of death. Pres
Phase 3 RASolute 302 trial of daraxonrasib in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. Median overall survival 13.2 months vs 6.7 months chemotherapy (HR 0.40, p<0.0001). The oral once-daily RAS(ON) multi-selective inhibitor from Revolution Medicines targets a protein long considered undruggable. Presented at ASCO 2026 Plenary in Chicago and published in NEJM. Phase 3 trial in lung cancer also underway.
Published on